MAAT PHARMA S.A. EO-1
MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in pivotal phase 3 clinical trial for the treatment of acute graft versus host diseases with gastrointestinal involvement; MaaT033, which is in phase 2b clinical trial for the improve… Read more
MAAT PHARMA S.A. EO-1 (4RD) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MAAT PHARMA S.A. EO-1 (4RD) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MAAT PHARMA S.A. EO-1 - Net Assets Trend (None–None)
This chart illustrates how MAAT PHARMA S.A. EO-1's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MAAT PHARMA S.A. EO-1 (None–None)
The table below shows the annual net assets of MAAT PHARMA S.A. EO-1 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MAAT PHARMA S.A. EO-1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MAAT PHARMA S.A. EO-1 Competitors by Market Cap
The table below lists competitors of MAAT PHARMA S.A. EO-1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Novem Group S.A.
F:NVM
|
$29.20 Million |
|
NFiniTi inc.
PINK:NFTN
|
$29.22 Million |
|
PENTIXAPHARM HOLDING N AG
XETRA:PTP
|
$29.25 Million |
|
Ledtech Electronics Corp
TW:6164
|
$29.26 Million |
|
RAC Electric Vehicles Inc.
TWO:2237
|
$29.19 Million |
|
Homenema Technology Incorporation
TWO:8087
|
$29.18 Million |
|
BAJAJINDEF
NSE:BAJAJINDEF
|
$29.18 Million |
|
CMUV Bancorp
OTCQB:CMUV
|
$29.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MAAT PHARMA S.A. EO-1's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MAAT PHARMA S.A. EO-1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MAAT PHARMA S.A. EO-1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MAAT PHARMA S.A. EO-1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,345,847,517
- Average return on equity (ROE) among peers: -601.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MAAT PHARMA S.A. EO-1 (4RD) | €- | N/A | N/A | $29.19 Million |
| 09R (09R) | $5.86 Million | -145.33% | 0.68x | $12.96 Million |
| IDORSIA AG (19T) | $104.20 Million | -608.99% | 13.23x | $582.75 Million |
| 1S90 (1S90) | $10.78 Million | -2319.92% | 31.35x | $54.21 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.28 Million |
| 25K0 (25K0) | $-79.67 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $508.00K | -2193.11% | 12.24x | $9.80 Million |
| Intervacc AB (publ) (2E9) | $308.25 Million | -9.53% | 0.07x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $3.03 Million | -558.03% | 2.82x | $9.20 Million |
| GNI Group Ltd (3G6) | $13.10 Billion | 1.39% | 0.57x | $772.60 Million |